Kalaris Therapeutics (NASDAQ:KLRS) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Kalaris Therapeutics (NASDAQ:KLRS – Free Report) from a sell rating to a hold rating in a report released on Monday,Wall Street Zen reports.

Separately, Weiss Ratings raised shares of Kalaris Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, November 4th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $18.75.

Check Out Our Latest Analysis on KLRS

Kalaris Therapeutics Price Performance

KLRS opened at $1.46 on Monday. The company’s 50 day simple moving average is $2.49 and its two-hundred day simple moving average is $5.02. Kalaris Therapeutics has a 1-year low of $1.41 and a 1-year high of $11.88. The firm has a market capitalization of $34.76 million, a price-to-earnings ratio of -0.79 and a beta of 0.47.

Kalaris Therapeutics (NASDAQ:KLRS – Get Free Report) last posted its quarterly earnings results on Tuesday, November 10th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.06. On average, equities analysts anticipate that Kalaris Therapeutics will post -1.92 earnings per share for the current fiscal year.

Institutional Trading of Kalaris Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KLRS. Goldman Sachs Group Inc. boosted its stake in shares of Kalaris Therapeutics by 146.8% in the third quarter. Goldman Sachs Group Inc. now owns 39,616 shares of the company’s stock valued at $114,000 after purchasing an additional 23,562 shares during the period. Empowered Funds LLC acquired a new stake in Kalaris Therapeutics during the 3rd quarter worth approximately $65,000. BlackRock Inc. purchased a new position in Kalaris Therapeutics in the 2nd quarter valued at approximately $222,000. Pale Fire Capital SE purchased a new position in Kalaris Therapeutics in the 2nd quarter valued at approximately $161,000. Finally, Velan Capital Investment Management LP boosted its position in Kalaris Therapeutics by 38.9% in the 2nd quarter. Velan Capital Investment Management LP now owns 25,000 shares of the company’s stock valued at $102,000 after buying an additional 7,000 shares during the period. Hedge funds and other institutional investors own 66.05% of the company’s stock.

Kalaris Therapeutics Company Profile

(Get Free Report)

Kalaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for retinal diseases. Its work centers on advancing investigational therapies intended to address conditions affecting vision. The company’s product candidates are in development and are not approved for commercial use. Kalaris’s activities include research and development and the clinical evaluation of potential therapies. Publicly available information about the company’s leadership and geographic operations is limited.

Featured Articles

Analyst Recommendations for Kalaris Therapeutics (NASDAQ:KLRS)

Receive News & Ratings for Kalaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.